Supplementary Table 2.
Risk of LT Recipients for No or Only a Low Humoral Immune Response After Second SARS-CoV-2 Vaccination Based on the RBD Immunoassay
| Univariate OR (95% CI) | P | Multivariate OR (95% CI) | P | |
|---|---|---|---|---|
| Age >65 y | 7.23 (2.55–20.53) | < .001 | 5.79 (1.90–17.70) | .002 |
| Sex (male) | 1.91 (0.96–3.80) | .066 | ||
| Vaccination regimen | 0.92 (0.45–1.86) | .811 | ||
| LT <1 y before vaccination | 2.35 (0.82–6.78) | .113 | ||
| Obesity (BMI ≥30 kg/m2) | 0.82 (0.30–2.22) | .699 | ||
| eGFR <45 mL/min | 9.12 (2.86–29.07) | < .001 | N/A | |
| Arterial hypertension | 2.62 (1.28–5.37) | .009 | 2.53 (1.13–5.65) | .024 |
| Diabetes | 2.24 (0.97–5.20) | .060 | ||
| CNI monotherapy | 0.23 (0.09–0.58) | .002 | 0.37 (0.13–1.05) | .063 |
| CNI + MMF | 3.63 (1.73–7.59) | .001 | 2.19 (0.92–5.19) | .077 |
| CNI + mTORi | 1.35 (0.49–3.73) | .563 | ||
| CNI + azathioprine | 0.13 (0.02–1.08) | .059 | ||
| CNI + prednisone | 0.64 (0.23–1.72) | .372 | ||
| No CNI | 5.14 (1.05–25.18) | .043 | ||
| Prednisone >5 mg | 0.96 (0.28–3.31) | .949 | ||
| Triple immunosuppression | 1.53 (0.56–4.14) | .405 | ||
| Biological | 3.72 (0.72–19.15) | .115 | ||
| Re-cirrhosis | 0.41 (0.10–1.60) | .197 | ||
| IgG <13.8 g/L | N/A | |||
| IgA <3.9 g/L | N/A | |||
| IgM <1.8 g/L | 4.13 (0.39–43.38) | .238 | ||
| Lymphocytes <1000/μl | 1.40 (0.47–4.20) | .548 | ||
| B-lymphocytes <80/μl | 4.33 (1.30–14.51) | .017 | N/A | |
| T-lymphocytes <900/μl | 0.82 (0.27–2.54) | .735 | ||
| NK-cells <35/μl | 0.54 (0.05–6.40) | .628 | ||
| CD4+ cells <400/μl | 0.86 (0.28–2.58) | .782 | ||
| CD8+ cells <290/μl | 0.83 (0.28–2.48) | .745 | ||
| CD4/CD8 ratio <0.6 | N/A | N/A |
Note: For laboratory values, the lower levels of normal were set as thresholds.
Note: Bold values indicate statistical significance.
BMI, Body mass index; CI, confidence interval; CNI, calcineurin inhibitor; eGFR, estimated glomular filtration rate; LT, liver transplantation; MMF, mycophenolate mofetil; mTORi, mTOR inhibitor; N/A, not applicable: laboratory values that were not considered for univariate or multivariate analysis because of insufficient baseline values; OR, odds ratio; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2.